Lv6
2170 积分 2024-02-20 加入
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study
2个月前
已完结
MARCO+ macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis
2个月前
已完结
Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials
3个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
4个月前
已完结
Non-invasive tests for evaluating treatment response in NAFLD
4个月前
已完结
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
4个月前
已完结
Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery
4个月前
已完结
Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor
5个月前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
5个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
